Reoviruses

Oncolytics Biotech® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T Cells in Solid Tumors

Retrieved on: 
Monday, April 5, 2021
Clinical medicine, Medicine, Virotherapy, Cancer immunotherapy, Branches of biology, Pelareorep, Reoviruses, Chimeric antigen receptor T cell, Immunotherapy, Oncolytics Biotech

(NASDAQ: ONCY) (TSX: ONC) today announced that it will host a Key Opinion Leader (KOL) webinar discussing AWARE-1 data, the immunotherapeutic effects of pelareorep in breast cancer, and its synergistic activity with CAR T cells in solid tumors.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a Key Opinion Leader (KOL) webinar discussing AWARE-1 data, the immunotherapeutic effects of pelareorep in breast cancer, and its synergistic activity with CAR T cells in solid tumors.
  • The webinar will feature presentations by Key Opinion Leaders Aleix Prat, M.D., Ph.D. (Clnic Barcelona) and Richard Vile, Ph.D., (Mayo Clinic).
  • Dr. Vile will then discuss the results of a preclinical study evaluating pelareorep and chimeric antigen receptor (CAR) T cell combination therapy in solid tumors ( link to PR, link to poster).
  • During the event, Oncolytics' management team will also give a corporate update and discuss the company's upcoming milestones.

Oncolytics Biotech® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T Cells in Solid Tumors

Retrieved on: 
Monday, April 5, 2021
Clinical medicine, Medicine, Virotherapy, Cancer immunotherapy, Branches of biology, Pelareorep, Reoviruses, Chimeric antigen receptor T cell, Immunotherapy, Oncolytics Biotech

(NASDAQ: ONCY) (TSX: ONC) today announced that it will host a Key Opinion Leader (KOL) webinar discussing AWARE-1 data, the immunotherapeutic effects of pelareorep in breast cancer, and its synergistic activity with CAR T cells in solid tumors.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a Key Opinion Leader (KOL) webinar discussing AWARE-1 data, the immunotherapeutic effects of pelareorep in breast cancer, and its synergistic activity with CAR T cells in solid tumors.
  • The webinar will feature presentations by Key Opinion Leaders Aleix Prat, M.D., Ph.D. (Clnic Barcelona) and Richard Vile, Ph.D., (Mayo Clinic).
  • Dr. Vile will then discuss the results of a preclinical study evaluating pelareorep and chimeric antigen receptor (CAR) T cell combination therapy in solid tumors ( link to PR, link to poster).
  • During the event, Oncolytics' management team will also give a corporate update and discuss the company's upcoming milestones.

Oncolytics Biotech® Establishes New At-The-Market Facility

Retrieved on: 
Friday, March 5, 2021
Virotherapy, Finance, Pelareorep, Reoviruses, Money, Technology, Oncolytic virus, NASDAQ, Automated teller machine, Oncolytics Biotech

The company has no obligation to sell any shares pursuant to the ATM.

Key Points: 
  • The company has no obligation to sell any shares pursuant to the ATM.
  • Sales of the ATM offering will only be conducted in the United States through NASDAQ or another exchange at market prices.
  • Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus.
  • The company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.

Oncolytics Biotech® Establishes New At-The-Market Facility

Retrieved on: 
Friday, March 5, 2021
Virotherapy, Finance, Pelareorep, Reoviruses, Money, Technology, Oncolytic virus, NASDAQ, Automated teller machine, Oncolytics Biotech

The company has no obligation to sell any shares pursuant to the ATM.

Key Points: 
  • The company has no obligation to sell any shares pursuant to the ATM.
  • Sales of the ATM offering will only be conducted in the United States through NASDAQ or another exchange at market prices.
  • Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus.
  • The company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Operational Highlights

Retrieved on: 
Friday, February 26, 2021
Clinical medicine, Pelareorep, Reoviruses, Virotherapy, Medical specialties, Medicine, Oncolytics Biotech, Cancer immunotherapy, Immune system, Oncolytic virus, Immune checkpoint

Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus.

Key Points: 
  • Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus.
  • The compound induces selective tumor lysis and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
  • Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved immuno-oncology agents.
  • The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Operational Highlights

Retrieved on: 
Friday, February 26, 2021
Clinical medicine, Pelareorep, Reoviruses, Virotherapy, Medical specialties, Medicine, Oncolytics Biotech, Cancer immunotherapy, Immune system, Oncolytic virus, Immune checkpoint

Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus.

Key Points: 
  • Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus.
  • The compound induces selective tumor lysis and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
  • Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved immuno-oncology agents.
  • The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.

Oncolytics Biotech® Reports Preclinical Data Demonstrating the Synergistic Anti-cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors

Retrieved on: 
Tuesday, February 23, 2021
Clinical medicine, Medicine, Cancer treatments, Virotherapy, Cancer immunotherapy, Immune system, Pelareorep, Reoviruses, Oncolytic virus, Immunotherapy, Checkpoint inhibitor, Virus

Pelareorep's ability to reverse immunosuppressive TMEs has been well documented in the clinic, and combining CAR T cells with pelareorep may enable their success against solid cancers.

Key Points: 
  • Pelareorep's ability to reverse immunosuppressive TMEs has been well documented in the clinic, and combining CAR T cells with pelareorep may enable their success against solid cancers.
  • In clinical studies, pelareorep recruited high concentrations of T cells to solid tumors, positioning it to synergistically interact with checkpoint inhibitors.
  • In this newly published study, we show the synergistic benefits of pelareorep can be extended to additional cutting-edge immunotherapeutic agents.
  • The electronic poster titled "Combination Therapy with Oncolytic Viruses and CAR T Cells," was developed in collaboration with researchers from the Mayo Clinic, Duke University, and Oncolytics.

Oncolytics Biotech® Reports Preclinical Data Demonstrating the Synergistic Anti-cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors

Retrieved on: 
Tuesday, February 23, 2021
Clinical medicine, Medicine, Cancer treatments, Virotherapy, Cancer immunotherapy, Immune system, Pelareorep, Reoviruses, Oncolytic virus, Immunotherapy, Checkpoint inhibitor, Virus

Pelareorep's ability to reverse immunosuppressive TMEs has been well documented in the clinic, and combining CAR T cells with pelareorep may enable their success against solid cancers.

Key Points: 
  • Pelareorep's ability to reverse immunosuppressive TMEs has been well documented in the clinic, and combining CAR T cells with pelareorep may enable their success against solid cancers.
  • In clinical studies, pelareorep recruited high concentrations of T cells to solid tumors, positioning it to synergistically interact with checkpoint inhibitors.
  • In this newly published study, we show the synergistic benefits of pelareorep can be extended to additional cutting-edge immunotherapeutic agents.
  • The electronic poster titled "Combination Therapy with Oncolytic Viruses and CAR T Cells," was developed in collaboration with researchers from the Mayo Clinic, Duke University, and Oncolytics.

Oncolytics Biotech® Announces Positive Clinical Results Against Glioblastoma Multiforme at the 2020 Society of Neuro-Oncology Annual Meeting

Retrieved on: 
Thursday, November 19, 2020
Health sciences, Medicine, Virotherapy, Clinical medicine, Pelareorep, Reoviruses, Aging-associated diseases, Brain tumor, Chemoradiotherapy, Therapy, Cancer, Oncolytics Biotech

The results, which were featured in a podium presentation at the 2020 Society of Neuro-Oncology Annual Meeting, show a compelling signal of efficacy and demonstrate the safety and tolerability of the pelareorep-based combination therapy in newly diagnosed GBM patients.

Key Points: 
  • The results, which were featured in a podium presentation at the 2020 Society of Neuro-Oncology Annual Meeting, show a compelling signal of efficacy and demonstrate the safety and tolerability of the pelareorep-based combination therapy in newly diagnosed GBM patients.
  • Together, these results drive momentum to develop pelareorep across a spectrum of cancer indications."
  • Oncolytics thanks the University of Leeds, Cancer Research UK, and The Brain Tumor Charity for designing, managing, and funding the ReoGlio trial.
  • The primary objective of the study was to determine the maximum tolerated dose of pelareorep and GM-CSF with standard chemoradiotherapy.

Oncolytics Biotech® Announces Positive Clinical Results Against Glioblastoma Multiforme at the 2020 Society of Neuro-Oncology Annual Meeting

Retrieved on: 
Thursday, November 19, 2020
Health sciences, Medicine, Virotherapy, Clinical medicine, Pelareorep, Reoviruses, Aging-associated diseases, Brain tumor, Chemoradiotherapy, Therapy, Cancer, Oncolytics Biotech

The results, which were featured in a podium presentation at the 2020 Society of Neuro-Oncology Annual Meeting, show a compelling signal of efficacy and demonstrate the safety and tolerability of the pelareorep-based combination therapy in newly diagnosed GBM patients.

Key Points: 
  • The results, which were featured in a podium presentation at the 2020 Society of Neuro-Oncology Annual Meeting, show a compelling signal of efficacy and demonstrate the safety and tolerability of the pelareorep-based combination therapy in newly diagnosed GBM patients.
  • Together, these results drive momentum to develop pelareorep across a spectrum of cancer indications."
  • Oncolytics thanks the University of Leeds, Cancer Research UK, and The Brain Tumor Charity for designing, managing, and funding the ReoGlio trial.
  • The primary objective of the study was to determine the maximum tolerated dose of pelareorep and GM-CSF with standard chemoradiotherapy.